Advertisement

AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation

  • AstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra (benralizumab) in Eosinophilic esophagitis (EoE) patients aged 12 years or older.

  • Eosinophilic esophagitis (EoE) is characterized by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus. Patients experience difficulty swallowing (dysphagia), pain, food getting stuck, and anxiety.

  • The data showed that Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.

  • Fasenra demonstrated a statistically significant improvement in histological disease remission but not a change in dysphagia symptoms compared to the placebo.

  • The trial included 210 patients who received either Fasenra or a placebo at four-week intervals.

  • The safety and tolerability profile for Fasenra in the trial was consistent with the known profile of the medicine.

  • Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma in the U.S., EU, Japan, and other countries and is approved for self-administration in the U.S., EU, and other countries.

  • Price Action: AZN shares are up 1.25% at $55.87 during the premarket session on the last check Tuesday.

See more from Benzinga

ADVERTISEMENT

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.